Loading
NASDAQHealthcareBiotechnology
Latest quote
$0.91
−$0.0101 · -1.10%
Werewolf Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing novel therapies that activate the body's immune system to combat cancer. Leveraging its exclusive PREDATOR platform, the company crafts conditionally activated molecules designed to stimulate both adaptive and innate immunity. This strategic approach aims to circumvent the shortcomings often associated with traditional proinflammatory immune treatments. Key among its product pipeline are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule targeting advanced solid tumors, and WTX-330, an Interleukin-12 INDUKINE molecule also designed for conditional activation, intended for advanced or metastatic solid tumors or lymphomas that have relapsed or are refractory. Furthermore, Werewolf Therapeutics is progressing WTX-613, a conditionally activated interferon alpha INDUKINE molecule, for addressing solid tumors and hematologic malignancies. The company was founded in 2017 and operates from its headquarters in Cambridge, Massachusetts.
Previous close
$0.91
−$0.0101 · -1.10%
Pre-market
$0.91
$0.00 · 0.00%
Oct 9, 5:20 AM ET
Regular session · ET · Market data may be delayed.
Werewolf Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing novel therapies that activate the body's immune system to combat cancer. Leveraging its exclusive PREDATOR platform, the company crafts conditionally activated molecules designed to stimulate both adaptive and innate immunity. This strategic approach aims to circumvent the shortcomings often associated with traditional proinflammatory immune treatments. Key among its product pipeline are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule targeting advanced solid tumors, and WTX-330, an Interleukin-12 INDUKINE molecule also designed for conditional activation, intended for advanced or metastatic solid tumors or lymphomas that have relapsed or are refractory. Furthermore, Werewolf Therapeutics is progressing WTX-613, a conditionally activated interferon alpha INDUKINE molecule, for addressing solid tumors and hematologic malignancies. The company was founded in 2017 and operates from its headquarters in Cambridge, Massachusetts.
Day range
Current $0.91
52-week range
Current $0.91
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
40
Expensive
Sentiment
31
Bearish
Risk
66
High Risk
Momentum
22
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Werewolf Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing novel therapies that activate the body's immune system to combat cancer. Leveraging its exclusive PREDATOR platform, the company crafts conditionally activated molecules designed to stimulate both adaptive and innate immunity. This strategic approach aims to circumvent the shortcomings often associated with traditional proinflammatory immune treatments. Key among its product pipeline are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule targeting advanced solid tumors, and WTX-330, an Interleukin-12 INDUKINE molecule also designed for conditional activation, intended for advanced or metastatic solid tumors or lymphomas that have relapsed or are refractory. Furthermore, Werewolf Therapeutics is progressing WTX-613, a conditionally activated interferon alpha INDUKINE molecule, for addressing solid tumors and hematologic malignancies. The company was founded in 2017 and operates from its headquarters in Cambridge, Massachusetts.
Day range
Current $0.91
52-week range
Current $0.91
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | 1.89M USD | 19.94M USD | 16.4M USD | — |
| Cost of goods sold | 1.63M USD | 1.81M USD | 1.76M USD | 2.51M USD | — |
| Gross profit | −1.63M USD | 71K USD | 18.18M USD | 13.89M USD | — |
| Research and development | 44.83M USD | 56.43M USD | 41.78M USD | 53.76M USD | 35.27M USD |
| Selling, general, and administrative | 15.85M USD | 19.05M USD | 18.67M USD | 21.5M USD | 14.82M USD |
| Operating expenses | 59.04M USD | 73.67M USD | 58.68M USD | 69.95M USD | 50.09M USD |
| Interest income | 3.11M USD | 6.67M USD | 7.42M USD | 1.91M USD | 104K USD |
| Interest expense | 5.27M USD | 4.66M USD | 3.14M USD | — | — |
| Depreciation and amortization | 1.63M USD | 1.81M USD | 1.76M USD | 1.1M USD | 216K USD |
| Operating income | −60.68M USD | −73.59M USD | −40.5M USD | −56.06M USD | −50.09M USD |
| Net income | −60.82M USD | −70.52M USD | −37.37M USD | −53.81M USD | −49.98M USD |
Company facts updated Oct 9, 2026.
Recent quarterly results
Recent quarterly results
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
